Xenetic Biosciences Inc (XBIO) Company Profile & Statistics

Xenetic Biosciences Inc
XBIO
(Nasdaq - US)
N/A
3.91
-0.05 (-1.15%)
in:usd•As of: May 16, 2024 10:29 UTC -4
Open
3.91
High
3.91
Low
3.91

About Xenetic Biosciences Inc

CEO

Jeffrey F. Eisenberg

Headquarters

945 concord st.

framingham, ma 01701, united states

Auditor

Marcum LLP

Employees

Share Holders

425

Website

www.xeneticbio.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen(TM), its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen(TM) has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

Xenetic Biosciences Inc Statistics

Valuation Measures

Market Capitalization ²	6.02M
Enterprise Value	-2.96M
Enterprise Value/EBITDA (ttm)	0.66
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	0.67
Price to Sales (ttm)	2.39
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-182.99%
Profit Margin (ttm)	-162.47%
Return on Equity (ttm)	-43.40%
Return on Invested Capital (ttm)	-37.16%
Return on Assets (ttm)	-40.03%

Income Statement

Revenue (ttm)	2.54M
Revenue Per Share (ttm)	1.65
Gross Profit (ttm)	2.54M
EBITDA (ttm)³	-4.52M
Net Income Avi to Common (ttm)	-4.13M
Diluted EPS (ttm)	-2.93

Share Statistics

Beta (5Y Monthly)	2.56
52-Week Change	33.45%
S&P500 52-Week Change	28.89%
S&P500 Member	No
Stock Optionable	No
Total Shares Outstanding ¹	1.54M
Dividend Yield	0.00%
Float ⁴	1.40M
% Held by Insiders	9.00%
% Held by Institutions	15.12%

Balance Sheet

Total Cash (mrq)	8.98M
Total Cash Per Share (mrq)	5.83
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	11.84%
Quick Ratio (mrq)	11.70%
Book Value Per Share (mrq)	6.36

Cash Flow

Operating Cash Flow Per Share (ytd)	-2.69
Free Cash Flow (ytd)	-4.11M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Xenetic Biosciences Inc

Trade With A Regulated Broker